This work was conducted with the aim of formulating the antihyperlipidemic statin; rousvastatin calcium (RVC) using silver nanoparticles (AgNPs) as a carrier. This delivery system was designed to make use of the nanoscale-enormous surface area of AgNPs in enhancing the anti-inflammatory characteristics of both the drug and the carrier. The probability of the occurrence of interaction between RVC and the excipients used in synthesizing AgNPs was investigated using differential scanning calorimetry (DSC) and Fourier transfer infrared spectroscopy (FT-IR)). Silver nanoparticles (AgNPs) were synthesized using different capping agents; PEG 6000, sodium alginate, polyvinyl alcohol (PVA) , β-cyclodextrin (β-CD), hydroxylpropyl-β-cyclodextrin (HPβ-CD) and Polyvinylpyrrolidone K90 (PVPK90). The silver nitrate was reduced using sodium borohydride. The formed AgNPs were then characterized by measuring their size and zeta potential and scanning electron microscopy (SEM). The results of DSC and Ft-IR revealed the absence of interaction between the used excipients and RVC. The loading capacity of AgNPs toward RVC was found to be dependent on the capping agent. The characterization of AgNPs by zeta analyzer shown the particle size diameter ranged from 184.7 to 812.1 nm depending on the capping agent. The values of zeta potential ranged from -32.8 to -10.5 Mv.